COVID-19 infection in patients with haematological disorders [COVID-19]
Research type
Research Study
Full title
COVID-19 infection in patients with haematological disorders
IRAS ID
282997
Contact name
Kirit Ardeshna
Contact email
Sponsor organisation
UCL/UCLH Joint Research Office
Duration of Study in the UK
1 years, 11 months, 5 days
Research summary
Background: As the outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) progresses, patients with underlying haematological diseases are vulnerable to infection. Both underlying haematological disease and the treatment of these disorders results in varying degrees of immunosuppression making this cohort of patients particularly vulnerable to COVID-19 infection. Epidemiological and clinical characteristics of patients with COVID-19 have been reported but outcomes in patients with underlying haematological disorders have not been described. \nAims: \n•\tTo describe the epidemiology and clinical course of COVID-19 infection in patients with underlying haematological disorders.\n•\tTo identify risk factors for severe disease and mortality within this cohort. \n\nType of Study: Observational Study\n\nAnonymised, routine clinical data available for patients managed at University College London Hospital with a diagnosis of COVID-19 infection and an underlying haematological disorder. \n
REC name
N/A
REC reference
N/A